Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers

Anatomical Record

Volumn 293, Issue 9, 2010, Pages 1506-1511

  Liao, Wangjun ^a   Liao, Yulin ^a   Zhou, Jeff X ^b   Xie, Jianming ^a   Chen, Jinzhang ^a   Huang, Weizhen ^a   Lou, Rongcheng ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Washington Hospital   (United States)

Author keywords

BRAF; Colorectal neoplasm; Epidermal growth factor receptor; KRAS; PIK3CA; Survival

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; BRAF PROTEIN, HUMAN; DNA; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

AGED; ARTICLE; CANCER SURVIVAL; CHINESE; COLORECTAL CANCER; CORRELATION ANALYSIS; FEMALE; GENE; GENE MUTATION; HUMAN; KRAS GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PYROSEQUENCING; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77956610320     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.21202     Document Type: Article

References (23)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634.
2. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. 1998. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90:675-684.
3. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent- Puig P, Piard F. 2008. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122:2255-2259.
4. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. 2004. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 351:2883.
5. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. 2009. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671.
6. Boyle P, Leon ME. 2002. Epidemiology of colorectal cancer. Br Med Bull 64:1-25.
7. Gillern SM, Chua TC, Stojadinovic A, Esquivel J. 2010. KRAS Status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. Am J Clin Oncol. [DOI: 10.1097/ COC.0b013e3181b4b160].
8. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. 2007. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357: 2040-2048.
9. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK. 2006. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914-4921.
10. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. 2006. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992-3995.
11. Mack GS. 2009. FDA holds court on post hoc data linking KRAS status to drug response. Nat Biotechnol 27:110-112.
12. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. 2005. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7:413-421.
13. Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB III, Goldberg RM, Bertagnolli MM, Fuchs CS. 2009. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15:7322-7329.
14. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
15. Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider- Stock R. 2007. K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 203:489-497.
16. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. 2009. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:5931-5937.
17. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F. 2010. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474.
18. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. 2009. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69:1851-1857.
19. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. 2009. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324.
20. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. 2009. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101:465-472.
21. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417.
22. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664.
23. Wei YS, Lu JC, Wang L, Lan P, Zhao HJ, Pan ZZ, Huang J, Wang JP. 2009. Risk factors for sporadic colorectal cancer in southern Chinese. World J Gastroenterol 15:2526-2530.